Piva R - Search Results

1

ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.

Martinengo C, Poggio T, Menotti M, Scalzo MS, Mastini C, Ambrogio C, Pellegrino E, Riera L, Piva R, Ribatti D, Pastorino F, Perri P, Ponzoni M, Wang Q, Voena C, Chiarle R. Martinengo C, et al. Among authors: piva r. Cancer Res. 2014 Nov 1;74(21):6094-106. doi: 10.1158/0008-5472.CAN-14-0268. Epub 2014 Sep 5. Cancer Res. 2014. PMID: 25193384

2

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death.

Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE, Inghirami G. Zamo A, et al. Among authors: piva r. Oncogene. 2002 Feb 7;21(7):1038-47. doi: 10.1038/sj.onc.1205152. Oncogene. 2002. PMID: 11850821

3

In vivo interference with Skp1 function leads to genetic instability and neoplastic transformation.

Piva R, Liu J, Chiarle R, Podda A, Pagano M, Inghirami G. Piva R, et al. Mol Cell Biol. 2002 Dec;22(23):8375-87. doi: 10.1128/MCB.22.23.8375-8387.2002. Mol Cell Biol. 2002. PMID: 12417738 Free PMC article.

4

NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors.

Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, Simmons WJ, Dhall G, Howes J, Piva R, Inghirami G. Chiarle R, et al. Among authors: piva r. Blood. 2003 Mar 1;101(5):1919-27. doi: 10.1182/blood-2002-05-1343. Epub 2002 Nov 7. Blood. 2003. PMID: 12424201 Free article.

5

New and old functions of STAT3: a pivotal target for individualized treatment of cancer.

Inghirami G, Chiarle R, Simmons WJ, Piva R, Schlessinger K, Levy DE. Inghirami G, et al. Among authors: piva r. Cell Cycle. 2005 Sep;4(9):1131-3. doi: 10.4161/cc.4.9.1985. Epub 2005 Sep 30. Cell Cycle. 2005. PMID: 16082218 Review.

6

p130Cas mediates the transforming properties of the anaplastic lymphoma kinase.

Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Boeri Erba E, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. Ambrogio C, et al. Among authors: piva r. Blood. 2005 Dec 1;106(12):3907-16. doi: 10.1182/blood-2005-03-1204. Epub 2005 Aug 16. Blood. 2005. PMID: 16105984 Free PMC article.

7

Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.

Piva R, Chiarle R, Manazza AD, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Piva R, et al. Blood. 2006 Jan 15;107(2):689-97. doi: 10.1182/blood-2005-05-2125. Epub 2005 Sep 27. Blood. 2006. PMID: 16189272 Free PMC article.

8

Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Piva R, Pellegrino E, Mattioli M, Agnelli L, Lombardi L, Boccalatte F, Costa G, Ruggeri BA, Cheng M, Chiarle R, Palestro G, Neri A, Inghirami G. Piva R, et al. J Clin Invest. 2006 Dec;116(12):3171-82. doi: 10.1172/JCI29401. Epub 2006 Nov 16. J Clin Invest. 2006. PMID: 17111047 Free PMC article.

9

Identification and validation of the anaplastic large cell lymphoma signature.

Piva R, Pellegrino E, Inghirami G. Piva R, et al. Adv Exp Med Biol. 2007;604:129-36. doi: 10.1007/978-0-387-69116-9_12. Adv Exp Med Biol. 2007. PMID: 17695725

10

The anaplastic lymphoma kinase in the pathogenesis of cancer.

Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. Chiarle R, et al. Among authors: piva r. Nat Rev Cancer. 2008 Jan;8(1):11-23. doi: 10.1038/nrc2291. Nat Rev Cancer. 2008. PMID: 18097461 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

321 results

Search Page

Filters